Actively Recruiting
Randomized, Double-Blind Crossover Trial Evaluating ASY202 Inhalation Powder Versus Placebo for Acute Migraine Treatment in Adults
Led by Aspeya, Inc. · Updated on 2026-10-09
108
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the investigational inhaled migraine medication ASY202 to assess its effectiveness, safety, and tolerability in adults with migraine. This Phase 2 clinical trial uses a randomized, double-blind, placebo-controlled, crossover design, involving adults aged 18 to 65 with a history of migraine. Participants will receive both ASY202 and placebo at different times during the study, without knowing which treatment they are receiving. The study is sponsored by Aspeya, Inc. and aims to better understand how ASY202 works for acute migraine treatment. Participants will use a handheld dry powder inhaler to take ASY202, a pre-metered dry powder formulation of dihydroergotamine DHE, during migraine attacks. The study includes two treatment periods separated by a washout period of at least 7 days. In Treatment Period 1, one group will receive ASY202 followed by placebo in Treatment Period 2, while the other group receives placebo first then ASY202. The placebo is an inactive inhalation powder delivered with a matching inhaler device. During the approximately 16-week study, participants will undergo screening, two treatment periods, and a safety follow-up visit. Researchers will monitor headache pain relief and freedom from pain at various timepoints post-dose, including 2 hours and up to 48 hours, as well as the use of rescue medication and functional ability. Safety assessments will track adverse events from screening through study completion. The study includes multiple visits to evaluate efficacy and tolerability throughout the trial.
CONDITIONS
Brief Title
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Research Team
E
Eken
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here